Company intelligence / Profile preview

Nordisk Rebalance A

Copenhagen, Denmark

Ownership: Private
Development stage: Other

Overview

Nordisk Rebalance is a clinical-stage biotechnology company based in Denmark that specializes in the development of live biotherapeutic products (LBPs) for gastrointestinal disorders. The company's lead candidate, RED101, is a multi-strain anaerobic bacterial consortium designed to restore microbial balance in patients with inflammatory bowel disease. Nordisk Rebalance is currently evaluating RED101 in Phase 2 clinical trials for the treatment of ulcerative colitis and pouchitis. By leveraging a targeted microbiome-based approach, the company aims to provide a safe and effective alternative to traditional immunosuppressive therapies.

Therapeutic areas: Gastroenterology
Modalities: Live biotherapeutic product therapyMicrobial therapy
Industry: Biotech

Beyond the preview

Go deeper on Nordisk Rebalance A.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nordisk Rebalance A.

Explore the full profile